Prof. P. Lambin has extensive experience with clinical trials. He has been one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 30 clinical trials). He has been also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He has been and is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, Eureca, Artforce, RADIATE, Quick-Concept, Requite, BD2decide, SCANnTREAT, EuCanImage, CHAIMELEON, DRAGON, iCOVID, AUTO.DISTINCT, LIVINGVAC, OPTIMA, AIDAVA, REALM, EUCAIM…) including ImmunoSABR (6 millions €, a multicentric randomized trial in metastatic lung cancer comparing radiotherapy plus or minus immunotherapy) and the Marie Curie Training network PREDICT of which he is the initiator and the coordinator and two NIH grant (“Radiomics”) form the US.